The revolutionary CAR-T cell remedy seeks to make its method past blood most cancers | Health & Wellness | EUROtoday

There is a most cancers therapy that, in only a decade, has revolutionized the prognosis of blood tumors. It is CAR-T cell remedy, an immense work of genetic engineering that consists of extracting T lymphocytes from the affected person – a sort of immune cells which might be liable for the physique's protection -, modifying them within the laboratory to make them simpler and returning them to the affected person. to allow them to higher struggle the tumor. It looks as if science fiction, its promoters admit, however it’s as actual because it has already given away 1000’s of unthinkable victories. And those that stay. CAR-T remedy has been efficiently established within the therapy of a handful of hematological cancers, resembling some leukemias or lymphomas, nevertheless it nonetheless has one pending situation: strong tumors, the place it has not achieved favorable outcomes. An investigation printed this Wednesday within the journal Science AdvancesHowever, it opens a brand new vein to take this revolutionary cell remedy past blood most cancers: in a research in animal fashions, scientists on the Montefiore Einstein Cancer Center in New York have proven {that a} extra highly effective and optimized model of CARs -T improves survival in mice with mind tumor, pancreatic and lung most cancers.

The biology of strong tumors, rather more advanced, has been the massive stone within the shoe to efficiently land CAR-T remedy past blood most cancers. Dr. very robust immunosuppressive tumor microenvironment, which inhibits CAR-T persistence and induces CAR-T exhaustion (lack of perform) alive“, Explain. It is also not easy to find tumor antigens on the surface of malignant cells, which are molecules that function as a kind of decoy, a letter of introduction to the tumor that helps the immune system identify which cells are malignant. In CAR-T therapies, antigen selection is key because the activity of genetically modified T lymphocytes is directed against tumor cells that express that particular antigen.

In his new research, Zang, who is also founding director of the Cancer Immunology Institute at Montefiore Einstein Comprehensive Cancer Center, has joined the scientific community's attempts to build new CAR-Ts that work better in solid tumors. And he has done it by redesigning parts of the structure of these molecular machines to create a more efficient and powerful CAR-T. His therapy, which uses two novel mechanisms, was tested in mice implanted with several types of human solid tumors.

The CAR-T designed by Zang's team—it is called TOP CAR (TMIGD2 Optimized Potent/Persistent CAR)—targets a new decoy, the B7-H3 antigen, a molecule present on tumor cells and unusual in tissue. healthy. “Our previous studies demonstrated that B7-H3 is widely expressed not only in human solid tumor cells, but also in the tumor vasculature, while it has a very limited expression in normal tissues,” explains the scientist. This new target, Zang assures, has advantages over others because “it can target many types of solid tumors” that present this antigen; “it has an antiangiogenic effect,” because it prevents the formation of blood vessels through which cancer can feed; and reduces the immunosuppression generated by this antigen in the tumor microenvironment.

But Zang has not only perfected the target of attack, he has strengthened his CAR-T with a new costimulator that helps activate T lymphocytes to attack tumor cells. “We wanted our CARs to not only bind T cells to solid tumors, but also, by specifically binding to B7-H3, prevent B7-H3 from interfering with the T cells' ability to attack and destroy cancer cells and their blood vessels,” the scientist justifies in a press release from his institution.

In an email conversation, Zang delves into this redesign of the CAR-T and underlines the advantages of this new costimulator, completely different from that used in other CAR-T therapies approved by the FDA (the US drug agency), he says. “Since 2017, the FDA has approved six CAR-T therapies that use [las proteínas] CD28 or 4-1BB as costimulators, which play important roles in activation/exhaustion and persistence of CAR-T cells. Our TOP CAR uses TMIGD2 as a costimulator, which is completely different from FDA approved CAR-T cells. Our TOP CAR established a lower percentage of exhausted cells, so CAR-T cells have better function; a higher percentage of central memory cells, so CAR-T cells have better function and persistence; a higher proportion of CD8/CD4 T cells within tumors, so CAR-T cells have a better ability to destroy tumors and fewer side effects; and they produced fewer cytokines, so CAR-T cells have better persistence and fewer side effects associated with cytokines,” he celebrates.

In terms of survival, in the animal models studied, Zang points out that, “compared to the third generation of CAR-T, the TOP CAR showed therapeutic efficiencies.” And he gives a couple of examples: the TOP CAR allowed seven of nine mice with glioblastoma (a brain tumor) to survive, while with the other CAR-T only three of nine did; In human pancreatic tumor models, four of seven mice treated with TOP CAR survived, while only one of seven managed to live after receiving third-generation CAR-T. “Based on our results, we want to bring this new therapy into clinical trials in cancer patients in the near future, particularly in solid tumors resistant to immune checkpoint inhibitors, such as cancers of the brain, liver, pancreas, ovary, prostate, etc.”, advances the scientist.

A first step

Zang's study is just a first step, a new path opened in the path that various research groups around the world are paving to perfect CAR-T and adapt them to different tumors, explains Alberto Mussetti, director of the Transplant Unit. of Hematopoietic Cells and Cellular Therapy of the Catalan Institute of Oncology of L'Hospitalet: “For solid tumors, CAR-T works very little or not at all. In many cases, because they are not able to attack the solid tumor. This study could be a promising strategy to overcome these resistances and is added to the list of attempts to build new CAR-Ts,” explains the hematologist, who has not participated in this research.

For his part, Francisco Aya, oncologist at the Hospital Clínic of Barcelona, ​​recalls that the great difficulties in delivering CAR-T to solid tumors are “finding a target antigen that is specific to the tumor and is not shared with other healthy tissues, and also that this therapy reaches the cancerous mass well, because these solid tumors may have a microenvironment around them that represses the attack of the immune system. “And in addition to recognizing the malignant cell, these CAR-Ts have to be accompanied by a costimulator that facilitates the cytotoxic response.” [de las células del sistema inmune para aniquilar el tumor]”. The doctor, who has not participated in Zang's research either, assures that this study “has found a different costimulator, which seems safer and improves the type of response” of the immune system. But he warns that the findings, for now, are in vivo and in vitro and it remains to be seen if the results translate when tested in humans. “This study is a reflection of the effort being made in the development of these therapies, but it is too early to be optimistic about these strategies. “I wouldn't throw the bells into the air,” he points out.

You can follow EL PAÍS Health and Wellbeing in Facebook, X e Instagram.